How many countries is Dabur in?
Dr Lal PathLabs provides diagnostic and healthcare testing services internationally across 23 countries, operating through an extensive network that includes more than 150 partner hospitals and reference laboratories. Alongside its massive domestic diagnostic infrastructure in India—which encompasses hundreds of labs and thousands of patient service collection points—its international operations help facilitate advanced clinical testing, specialized pathology, and molecular diagnostics daily.
Related FAQs
The long-term outlook for Dabur India suggests potential growth, with analysts projecting a target of Rs 591.8 by fiscal year 2028, contingent on sustained earnings growth and potential sector multiple re-ratings.
Whether Dabur is a good stock to buy depends on your investment horizon and risk tolerance. With a base case target of Rs 486.2 for 2026 and long-term potential reaching Rs 591.
Yes, Dabur is a profitable company. For the fourth quarter of the 2025-26 fiscal year, Dabur India reported a consolidated net profit of Rs 362 Crore, which was a 16% increase from Rs 312.7 Crore in the previous year.
Dabur maintains a documented commitment to ethical conduct through its Code of Conduct, which applies to all directors and employees.
No, Dabur India is not debt-free. As of March 2026, the company's current portion of total debt was 10.902 billion. While the company has actively managed its liabilities over the past five years—with debt levels fluctuating between a low of 4.